

## OP CISPLATIN / PACLITAXEL

*Types:* ONCOLOGY TREATMENT

*Synonyms:* SIS, CISPLATIN, PACLITAXEL, TAXOL, PLATINOL, PAX, TACK, GYNECOLOGIC , MALIGNANCY , NON SMALL CELL LUNG CANCER, NSCLC

<b>Cycles 1 to 4</b>	Repeat 4 times	Cycle length: 21 days
<b>Day 1</b>	Perform every 1 day x1	
<b>Appointment Requests</b>		
<b>INFUSION APPOINTMENT REQUEST</b>		
Interval: --	Occurrences: --	
<b>Labs</b>		
<input checked="" type="checkbox"/> <b>COMPREHENSIVE METABOLIC PANEL</b>	Interval: -- Occurrences: --	
<input checked="" type="checkbox"/> <b>CBC WITH PLATELET AND DIFFERENTIAL</b>	Interval: -- Occurrences: --	
<input checked="" type="checkbox"/> <b>MAGNESIUM LEVEL</b>	Interval: -- Occurrences: --	
<input type="checkbox"/> <b>CANCER ANTIGEN 125</b>	Interval: -- Occurrences: --	
<input type="checkbox"/> <b>LDH</b>	Interval: -- Occurrences: --	
<input type="checkbox"/> <b>URIC ACID LEVEL</b>	Interval: -- Occurrences: --	
<b>Outpatient Electrolyte Replacement Protocol</b>		
<b>TREATMENT CONDITIONS 39</b>		
Interval: --	Occurrences: --	
Comments:	Potassium (Normal range 3.5 to 5.0mEq/L) <ul style="list-style-type: none"> <li>o Protocol applies for SCr less than 1.5. Otherwise, contact MD/NP</li> <li>o Protocol applies only to same day lab value.</li> <li>o Serum potassium less than 3.0mEq/L, give 40mEq KCL IV or PO and contact MD/NP</li> <li>o Serum potassium 3.0 to 3.2mEq/L, give 40mEq KCL IV or PO</li> <li>o Serum potassium 3.3 to 3.4mEq/L, give 20mEq KCL IV or PO</li> <li>o Serum potassium 3.5 mEq/L or greater, do not give potassium replacement</li> <li>o If patient meets criteria, order SmartSet called "Outpatient Electrolyte Replacement"</li> <li>o Sign electrolyte replacement order as Per protocol: cosign required</li> </ul>	
<b>TREATMENT CONDITIONS 40</b>		
Interval: --	Occurrences: --	
Comments:	Magnesium (Normal range 1.6 to 2.6mEq/L) <ul style="list-style-type: none"> <li>o Protocol applies for SCr less than 1.5. Otherwise, contact MD/NP</li> <li>o Protocol applies only to same day lab value.</li> <li>o Serum Magnesium less than 1.0mEq/L, give 2 gram magnesium sulfate IV and contact MD/NP</li> <li>o Serum Magnesium 1.0 to 1.2mEq/L. give 2 gram magnesium</li> </ul>	

- sulfate IV
  - o Serum Magnesium 1.3 to 1.5mEq/L, give 1 gram magnesium sulfate IV
  - o Serum Magnesium 1.6 mEq/L or greater, do not give magnesium replacement
  - o If patient meets criteria, order SmartSet called "Outpatient Electrolyte Replacement"
  - o Sign electrolyte replacement order as Per protocol: cosign required

**Nursing Orders**

**TREATMENT CONDITIONS 12**

Interval: -- Occurrences: --  
 Comments: HOLD and notify provider if ANC LESS than 1000; Platelets LESS than 100,000; SCr GREATER than 1.5

**Line Flush**

**sodium chloride 0.9 % flush 20 mL**  
 Dose: 20 mL Route: intravenous PRN  
 Start: S

**Pre-Hydration**

**sodium chloride 0.9 % infusion 1,000 mL**  
 Dose: 1,000 mL Route: intravenous once @ 500 mL/hr for 1 dose  
 Start: S

**Pre-Medications**

**palonosetron (ALOXI) injection 0.25 mg**  
 Dose: 0.25 mg Route: intravenous once for 1 dose  
 Start: S End: S 1:45 PM

**dexamethasone (DECADRON) 12 mg in sodium chloride 0.9% IVPB**  
 Dose: 12 mg Route: intravenous once over 15 Minutes for 1 dose  
 Start: S

Ingredients:	Name	Type	Dose	Selected	Adds Vol.
	DEXAMETHASONE 4 MG/ML INJECTION SOLUTION	Medications	12 mg	Main Ingredient	Yes
	SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	Base	50 mL	Yes	Yes
	DEXTROSE 5 % IN WATER (D5W) INTRAVENOUS SOLUTION	Base	50 mL	No	Yes

**aprepitant (CINVANTI) 130 mg in dextrose (NON-PVC) 5% 130 mL IVPB**  
 Dose: 130 mg Route: intravenous once over 30 Minutes for 1 dose  
 Start: S End: S

Ingredients:	Name	Type	Dose	Selected	Adds Vol.
	APREPITANT 7.2 MG/ML INTRAVENOUS EMULSION	Medications	130 mg	Main Ingredient	Yes
	DEXTROSE 5 % IN WATER (D5W) IV SOLP (EXCEL; NON-PVC) SODIUM	Base	130 mL	Yes	Yes
		Base	130 mL	No	Yes

CHLORIDE 0.9 % IV  
SOLP  
(EXCEL;NON-PVC)

**netupitant-palonosetron (AKYNZEO) 300-0.5 mg per capsule 1 capsule**

Dose: 1 capsule      Route: oral      once for 1 dose  
Start: S      End: S 5:30 PM  
Instructions:  
Administer approximately 1 hour prior to chemotherapy.

Pre-Medications

**diphenhydrAMINE (BENADRYL) injection 25 mg**

Dose: 25 mg      Route: intravenous      once for 1 dose  
Offset: 0 Hours

Instructions:  
Administer 30 minutes prior to chemotherapy via slow IVP.

**diphenhydrAMINE (BENADRYL) 50 mg in sodium chloride 0.9 % 50 mL IVPB**

Dose: 50 mg      Route: intravenous      once over 15 Minutes for 1 dose  
Start: S      End: S 11:00 AM

Instructions:  
Administer 30 minutes prior to chemotherapy

Ingredients:	Name	Type	Dose	Selected	Adds Vol.
	DIPHENHYDRAMIN E 50 MG/ML INJECTION SOLUTION	Medications	50 mg	Main Ingredient	No
	SODIUM CHLORIDE 0.9 % INTRAVENOUS SOLUTION	Base	50 mL	Yes	Yes
	DEXTROSE 5 % IN WATER (D5W) INTRAVENOUS SOLUTION	Base	50 mL	No	Yes

**diphenhydrAMINE (BENADRYL) tablet 25 mg**

Dose: 25 mg      Route: oral      once for 1 dose  
Offset: 0 Hours

Instructions:  
Administer 30 minutes prior to chemotherapy.

**famotidine (PEPCID) 20 mg/2 mL injection 20 mg**

Dose: 20 mg      Route: intravenous      once for 1 dose  
Offset: 0 Hours

Instructions:  
Administer 30 minutes prior to chemotherapy.

**famotidine (PEPCID) tablet 20 mg**

Dose: 20 mg      Route: oral      once for 1 dose  
Offset: 0 Hours

Instructions:  
Administer 30 minutes prior to chemotherapy.

**dexamethasone (DECADRON) injection 20 mg**

Dose: 20 mg      Route: intravenous      once for 1 dose  
Offset: 0 Hours

Pre-Medications



**HEParin, porcine (PF) injection 500 Units**

Dose: 500 Units                      Route: intra-catheter      once PRN

Start: S

Instructions:

Concentration: 100 units/mL. Heparin flush for  
Implanted Vascular Access Device  
maintenance.

Post-Medications

**pegfilgrastim (NEULASTA) on-body injection  
kit 6 mg**

Dose: 6 mg                              Route: subcutaneous      once for 1 dose

Start: S                                  End: S

Instructions:

Apply to intact, nonirritated skin on the back of  
the arm or abdomen (only use the back of the  
arm if caregiver is available to monitor  
On-body injection status).